Insider · SEC Form 4 filer

Carl Gordon

Past buys: 2 of 3 beat

Companies

Where they file as an insider

Electra Therapeutics (ETRA) Director, 10% owner Latest filing Nov 10, 2026
ADARx Pharmaceuticals (ADRX) Director, 10% owner Latest filing Sep 28, 2026
BlossomHill Therapeutics (BLSM) Director Latest filing Aug 10, 2026
Scribe Therapeutics (SCTX) Director Latest filing Jul 27, 2026
Keros Therapeutics (KROS) Director Latest filing Nov 21, 2025
Compass Therapeutics (CMPX) Director, 10% owner Latest filing Apr 9, 2025
MBX Biosciences (MBX) Director, 10% owner Latest filing Feb 18, 2025
Lomond Therapeutics Director Latest filing Nov 1, 2024

And 6 more companies with older filings.

Track record

Did their buys beat the typical stock?

Open-market buys33
Quarters checked 6 months later3
Beat the typical stock 2 of 3
Quarters too new to check5

2 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.

Electra Therapeutics (ETRA) Bought Nov 3–10, 2026 · $4.35M · 564,687 shares Too new Too new. Its 6-month check uses prices as of Jun 30, 2027.
ADARx Pharmaceuticals (ADRX) Bought Sep 28, 2026 · $16.1M · 950,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Electra Therapeutics (ETRA) Bought Sep 21, 2026 · $20M · 1.33M shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
BlossomHill Therapeutics (BLSM) Bought Aug 10, 2026 · $10M · 625,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Scribe Therapeutics (SCTX) Bought Jul 27, 2026 · $15M · 1M shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
MBX Biosciences (MBX) Bought Feb 14–18, 2025 · $2.02M · 190,672 shares Beat typical Mar 31, 2025 $7.38 → Sep 30, 2025 $17.50 · +137.1% (typical stock +7.3%)
MBX Biosciences (MBX) Bought Sep 16, 2024 · $12M · 750,000 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2024 and Mar 31, 2025.
ArriVent Biopharma (AVBP) Bought Jan 30, 2024 · $4M · 222,222 shares Beat typical Mar 31, 2024 $17.86 → Sep 30, 2024 $23.50 · +31.6% (typical stock +3.2%)
Adicet Bio (ACET) Bought Jan 25, 2024 · $7.5M · 3.12M shares Behind typical Mar 31, 2024 $2.35 → Sep 30, 2024 $1.44 · −38.7% (typical stock +3.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist